Every Selank (Tuftsin Analogue) Question Answered, in 17 Studies

17 referenced articles

• What Is Selank? Sequence, Origin and Enkephalin Mechanism4 sources
• What an Aversive-Signs Model Measures2 sources
• An Induced-Deficit Model With a Biochemical Readout2 sources
• Why Proline Keeps Appearing in These Sequences3 sources
• Tuftsin and the Antigenicity Question3 sources
• The Question the Fragment Literature Does Not Answer3 sources
• A Co-Receptor That Binds Almost Nothing in Common2 sources
• The Parent Has a Receptor the Analogue Lacks3 sources
• Selank Regulatory Status4 sources
• Selank in the Published Literature4 sources
• Selank Storage, Stability and Reconstitution2 sources
• Selank CAS Number and Chemical Identity2 sources
• Selank Structure, Sequence and Physical Properties2 sources
• Selank and BDNF: What the Studies Measured2 sources
• Selank and GABAergic Signalling3 sources
• Selank's Enkephalinase Mechanism2 sources
• What Is Tuftsin? An Immunopeptide From Antibody3 sources

Open research questions

• What is Selank?
• What is tuftsin?
• How does Selank affect enkephalins?
• Does Selank work like a benzodiazepine?
• Is Selank approved in the UK?
• How does Selank differ from Semax?

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue - and instructively, that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin - an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Handling checklist

• Store lyophilised material cold, dry and protected from light
• No reducing agent needed — the sequence contains no cysteine
• No methionine oxidation to expect; a +16 Da satellite warrants explanation
• Do not rely on 280 nm absorbance — there are no aromatic residues
• Introduce diluent gently against the vial wall; swirl rather than shake
• Aliquot to avoid repeated freeze-thaw cycles

Common mistakes

Describing Selank as an opioid or opioid agonist

Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

Treating the benzodiazepine contrast as a safety claim

The mechanistic difference is real — expression-level rather than direct allosteric modulation — but it supports no comparative claim about safety or dependence.

Citing tuftsin literature as evidence about Selank

Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

Reading a BDNF expression change as a demonstrated outcome

The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

Treating Russian registration as equivalent to MHRA approval

Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.